Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
The anticancer agent indisulam has a nonlinear pharmacokinetic profile, which may be partly related to saturable binding to blood constituents. To gain insight into the complex nonlinear behavior of indisulam, we investigated binding to plasma proteins and erythrocytes. The purpose of the study was to develop a physiological model for the distribution of indisulam in blood. Concentrations of radiolabeled indisulam were measured in vitro 1) in total plasma and in ultrafiltrate to investigate plasma protein binding, 2) in erythrocytes and in plasma to investigate distribution to erythrocytes, and 3) in erythrocyte membranes to investigate nonspecific binding in erythrocytes. For in vivo assessment, 21 patients received 400 to 900 mg/m2 indisulam in a 1- or 2-h infusion. Total and free concentrations in plasma and concentrations in erythrocytes were determined at multiple time points. In vitro plasma protein binding was described by a Langmuir model with a maximal binding capacity (Bmax = 767 microM) and an equilibrium dissociation constant (KD = 1.02 microM). The maximal capacity of plasma protein binding in vivo corresponded to albumin levels. The bound concentration in erythrocytes was described by a two-site model, comprising a saturable and a nonspecific binding component. The saturable component (Bmax = 174 microM) may correspond to binding to carbonic anhydrase. The physiological model adequately described the nonlinear disposition of indisulam in whole blood. Indisulam was bound to plasma proteins and distributed to erythrocytes in a saturable manner. These saturable processes may be attributed to binding to albumin (in plasma) and to carbonic anhydrase (in erythrocytes).
Zandvliet
Anthe S
AS
Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands. apaza@slz.nl
Copalu
William
W
Schellens
Jan H M
JH
Beijnen
Jos H
JH
Huitema
Alwin D R
AD
D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics; D002250:Carbon Radioisotopes; D002256:Carbonic Anhydrases / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D004910:Erythrocyte Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D013449:Sulfonamides / Q000097:blood* / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; C439829:N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; D012709:Serum Albumin; D013449:Sulfonamides; D002256:Carbonic Anhydrases